LRRK2 monoclonal antibodies (Epitomics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLRRK2 monoclonal antibodies (Epitomics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 modulators
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEpitomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEpitomics Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A